vs
Side-by-side financial comparison of Azenta, Inc. (AZTA) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
Azenta, Inc. is the larger business by last-quarter revenue ($148.6M vs $75.5M, roughly 2.0× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 0.8%). Azenta, Inc. produced more free cash flow last quarter ($14.7M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 4.4%).
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
AZTA vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.6M | $75.5M |
| Net Profit | $-15.4M | — |
| Gross Margin | 42.9% | 69.3% |
| Operating Margin | -4.9% | 22.7% |
| Net Margin | -10.4% | — |
| Revenue YoY | 0.8% | 27.7% |
| Net Profit YoY | -15.7% | — |
| EPS (diluted) | $-0.34 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.6M | $75.5M | ||
| Q3 25 | $159.2M | $54.5M | ||
| Q2 25 | $143.9M | $52.4M | ||
| Q1 25 | $143.3M | $46.0M | ||
| Q4 24 | $147.4M | $59.1M | ||
| Q3 24 | $150.6M | $80.5M | ||
| Q2 24 | $144.3M | $47.1M | ||
| Q1 24 | $136.4M | $43.8M |
| Q4 25 | $-15.4M | — | ||
| Q3 25 | $50.9M | $8.8M | ||
| Q2 25 | $-48.0M | $5.9M | ||
| Q1 25 | $-47.7M | $3.0M | ||
| Q4 24 | $-11.0M | — | ||
| Q3 24 | $-6.6M | $20.3M | ||
| Q2 24 | $-6.6M | $-4.5M | ||
| Q1 24 | $-137.4M | $-4.8M |
| Q4 25 | 42.9% | 69.3% | ||
| Q3 25 | 45.4% | 77.7% | ||
| Q2 25 | 46.2% | 76.5% | ||
| Q1 25 | 43.8% | 77.1% | ||
| Q4 24 | 46.7% | 76.4% | ||
| Q3 24 | 45.5% | 63.9% | ||
| Q2 24 | 44.8% | 77.4% | ||
| Q1 24 | 43.8% | 75.5% |
| Q4 25 | -4.9% | 22.7% | ||
| Q3 25 | 1.2% | 17.6% | ||
| Q2 25 | -1.3% | 12.7% | ||
| Q1 25 | -12.7% | 8.7% | ||
| Q4 24 | -5.9% | 22.6% | ||
| Q3 24 | -3.1% | 27.4% | ||
| Q2 24 | -4.9% | -4.6% | ||
| Q1 24 | -18.1% | -5.3% |
| Q4 25 | -10.4% | — | ||
| Q3 25 | 32.0% | 16.2% | ||
| Q2 25 | -33.4% | 11.2% | ||
| Q1 25 | -33.3% | 6.5% | ||
| Q4 24 | -7.5% | — | ||
| Q3 24 | -4.4% | 25.2% | ||
| Q2 24 | -4.5% | -9.6% | ||
| Q1 24 | -100.8% | -11.0% |
| Q4 25 | $-0.34 | $0.26 | ||
| Q3 25 | $1.12 | $0.17 | ||
| Q2 25 | $-1.05 | $0.12 | ||
| Q1 25 | $-1.04 | $0.06 | ||
| Q4 24 | $-0.25 | $0.40 | ||
| Q3 24 | $-0.25 | $0.41 | ||
| Q2 24 | $-0.12 | $-0.09 | ||
| Q1 24 | $-2.48 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $336.6M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $1.7B | $130.3M |
| Total Assets | $2.1B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $336.6M | $97.5M | ||
| Q3 25 | $279.8M | $94.4M | ||
| Q2 25 | $270.0M | $96.0M | ||
| Q1 25 | $253.6M | $93.2M | ||
| Q4 24 | $377.5M | $101.0M | ||
| Q3 24 | $280.0M | $96.7M | ||
| Q2 24 | $336.5M | $96.8M | ||
| Q1 24 | $353.5M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $1.7B | $130.3M | ||
| Q3 25 | $1.7B | $115.3M | ||
| Q2 25 | $1.7B | $104.7M | ||
| Q1 25 | $1.7B | $97.1M | ||
| Q4 24 | $1.7B | $92.1M | ||
| Q3 24 | $1.8B | $71.1M | ||
| Q2 24 | $2.0B | $48.5M | ||
| Q1 24 | $2.2B | $51.0M |
| Q4 25 | $2.1B | $216.3M | ||
| Q3 25 | $2.1B | $202.9M | ||
| Q2 25 | $2.0B | $194.9M | ||
| Q1 25 | $2.0B | $196.2M | ||
| Q4 24 | $2.0B | $213.3M | ||
| Q3 24 | $2.1B | $220.7M | ||
| Q2 24 | $2.3B | $205.0M | ||
| Q1 24 | $2.6B | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.8M | $14.4M |
| Free Cash FlowOCF − Capex | $14.7M | $14.4M |
| FCF MarginFCF / Revenue | 9.9% | 19.1% |
| Capex IntensityCapex / Revenue | 4.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $30.9M | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.8M | $14.4M | ||
| Q3 25 | $2.2M | $9.7M | ||
| Q2 25 | $25.8M | $14.1M | ||
| Q1 25 | $14.4M | $3.6M | ||
| Q4 24 | $29.8M | $15.6M | ||
| Q3 24 | $17.7M | $11.0M | ||
| Q2 24 | $9.8M | $1.0M | ||
| Q1 24 | $8.7M | $11.2M |
| Q4 25 | $14.7M | $14.4M | ||
| Q3 25 | $-5.7M | $9.7M | ||
| Q2 25 | $15.0M | $14.1M | ||
| Q1 25 | $7.0M | $3.6M | ||
| Q4 24 | $22.0M | $15.6M | ||
| Q3 24 | $8.3M | $11.0M | ||
| Q2 24 | $1.3M | $1.0M | ||
| Q1 24 | $428.0K | — |
| Q4 25 | 9.9% | 19.1% | ||
| Q3 25 | -3.6% | 17.7% | ||
| Q2 25 | 10.4% | 26.8% | ||
| Q1 25 | 4.9% | 7.7% | ||
| Q4 24 | 15.0% | 26.4% | ||
| Q3 24 | 5.5% | 13.7% | ||
| Q2 24 | 0.9% | 2.1% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 4.2% | 0.0% | ||
| Q3 25 | 4.9% | 0.0% | ||
| Q2 25 | 7.5% | 0.0% | ||
| Q1 25 | 5.2% | 0.1% | ||
| Q4 24 | 5.3% | 0.0% | ||
| Q3 24 | 6.2% | 0.0% | ||
| Q2 24 | 5.9% | 0.0% | ||
| Q1 24 | 6.1% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.04× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
PBYI
Segment breakdown not available.
